dvx201
Cell therapyexperimental
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Aug 2, 2021 (NCT04900454)
Timeline
2020s
- Jan 1, 2021
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Tumor antigensImmunity, passive
immunity, passive - tumor antigens
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04901416 | Phase 1 | Dec 15, 2021 | Deverra Therapeutics, Inc., Duke University |
| NCT04900454 | Phase 1 | Aug 2, 2021 | Deverra Therapeutics, Inc., University of Washington |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Deverra Therapeutics, Inc. | For profit | 2 | 2 | 1 | 2021 |
| Duke University | Academic/Hospital | 1 | 0 | 1 | 2021 |
| University of Washington | Academic/Hospital | 1 | 0 | 1 | 2021 |
3 organizations
Page 1 / 1